These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3436638)

  • 1. Heterologous protection in murine cutaneous leishmaniasis.
    Mitchell GF; Handman E
    Immunol Cell Biol; 1987 Oct; 65 Pt 5():387-92. PubMed ID: 3436638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease-promoting antigen in murine cutaneous leishmaniasis.
    Mitchell GF; Handman E
    Parasite Immunol; 1986 May; 8(3):255-63. PubMed ID: 2425330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis.
    Handman E; Mitchell GF
    Proc Natl Acad Sci U S A; 1985 Sep; 82(17):5910-4. PubMed ID: 3862105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody identification of Leishmania tropica from Sudanese mucosal leishmaniasis.
    Mohammed el-A ; Wright EP
    Trop Med Parasitol; 1987 Mar; 38(1):34-6. PubMed ID: 3299657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.
    Jaffe CL; Rachamim N; Sarfstein R
    J Immunol; 1990 Jan; 144(2):699-706. PubMed ID: 2295807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An immunologic method of producing antigens for the treatment and prevention of leishmaniasis].
    Vouldoukis I; Monjour L
    C R Acad Sci III; 1989; 308(5):129-34. PubMed ID: 2493318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P; Pearce E; Natovitz P; Sher A
    J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.
    Scott P; Pearce E; Natovitz P; Sher A
    J Immunol; 1987 Nov; 139(9):3118-25. PubMed ID: 3499465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of integral membrane proteins of Leishmania major by Triton X-114 fractionation and analysis of vaccination effects in mice.
    Murray PJ; Spithill TW; Handman E
    Infect Immun; 1989 Jul; 57(7):2203-9. PubMed ID: 2731987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assessment of anti-Leishmania immunity of man acquired with a vaccine.
    Vouldoukis I; Ogunkolade BW; Frommel D; Alier N; Monjour L
    Experientia; 1988 Jan; 44(1):56-7. PubMed ID: 3350121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
    Sadick MD; Locksley RM; Tubbs C; Raff HV
    J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.
    Monjour L; Vouldoukis I; Ogunkolade BW; Hetzel C; Ichen M; Frommel D
    Trans R Soc Trop Med Hyg; 1988; 82(3):412-5. PubMed ID: 3232174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
    Thakur A; Kaur H; Kaur S
    Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies to Leishmania tropica major: specificities and antigen location.
    de Ibarra AA; Howard JG; Snary D
    Parasitology; 1982 Dec; 85 (Pt 3)():523-31. PubMed ID: 6184664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.